TW202308616A - 用於增加紅血球及／或血紅素之組成物 - Google Patents
用於增加紅血球及／或血紅素之組成物 Download PDFInfo
- Publication number
- TW202308616A TW202308616A TW111115162A TW111115162A TW202308616A TW 202308616 A TW202308616 A TW 202308616A TW 111115162 A TW111115162 A TW 111115162A TW 111115162 A TW111115162 A TW 111115162A TW 202308616 A TW202308616 A TW 202308616A
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- ergothioneine
- salt
- hemoglobin
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 135
- 210000003743 erythrocyte Anatomy 0.000 title claims abstract description 71
- 102000001554 Hemoglobins Human genes 0.000 title claims abstract description 68
- 108010054147 Hemoglobins Proteins 0.000 title claims abstract description 68
- 230000001965 increasing effect Effects 0.000 title claims abstract description 56
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims abstract description 108
- 150000003839 salts Chemical class 0.000 claims abstract description 84
- 208000007502 anemia Diseases 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 40
- 230000002929 anti-fatigue Effects 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims description 68
- 210000004369 blood Anatomy 0.000 claims description 60
- 239000008280 blood Substances 0.000 claims description 60
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 58
- 230000007103 stamina Effects 0.000 claims description 36
- 229960003080 taurine Drugs 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 description 35
- 206010016256 fatigue Diseases 0.000 description 34
- 239000003814 drug Substances 0.000 description 27
- 241000282414 Homo sapiens Species 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 229940079593 drug Drugs 0.000 description 14
- 230000008859 change Effects 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000007689 inspection Methods 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 238000004820 blood count Methods 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 229940093497 ergothioneine Drugs 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010033557 Palpitations Diseases 0.000 description 4
- 206010034568 Peripheral coldness Diseases 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- -1 inorganic acid salts Chemical class 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000222350 Pleurotus Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 240000008397 Ganoderma lucidum Species 0.000 description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 2
- 240000001080 Grifola frondosa Species 0.000 description 2
- 235000007710 Grifola frondosa Nutrition 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 240000000588 Hericium erinaceus Species 0.000 description 2
- 235000007328 Hericium erinaceus Nutrition 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 240000000599 Lentinula edodes Species 0.000 description 2
- 206010024870 Loss of libido Diseases 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 206010027339 Menstruation irregular Diseases 0.000 description 2
- 240000002769 Morchella esculenta Species 0.000 description 2
- 235000002779 Morchella esculenta Nutrition 0.000 description 2
- 240000001462 Pleurotus ostreatus Species 0.000 description 2
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000008043 acidic salts Chemical class 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 244000251953 Agaricus brunnescens Species 0.000 description 1
- 240000001538 Agaricus subrufescens Species 0.000 description 1
- 235000008610 Agaricus subrufescens Nutrition 0.000 description 1
- 244000045069 Agrocybe aegerita Species 0.000 description 1
- 235000008121 Agrocybe aegerita Nutrition 0.000 description 1
- 241000404030 Anacyclus clavatus Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000222455 Boletus Species 0.000 description 1
- 241001489124 Boletus edulis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000191482 Cantharellus cibarius Species 0.000 description 1
- 235000015722 Cantharellus cibarius Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241001492261 Pleurotaceae Species 0.000 description 1
- 241000392443 Pleurotus citrinopileatus Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000036997 mental performance Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021-074320 | 2021-04-26 | ||
| JP2021074320 | 2021-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202308616A true TW202308616A (zh) | 2023-03-01 |
Family
ID=83847365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111115162A TW202308616A (zh) | 2021-04-26 | 2022-04-21 | 用於增加紅血球及／或血紅素之組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240180876A1 (https=) |
| EP (1) | EP4331580A4 (https=) |
| JP (1) | JPWO2022230487A1 (https=) |
| CN (1) | CN117202904A (https=) |
| AU (1) | AU2022267109A1 (https=) |
| TW (1) | TW202308616A (https=) |
| WO (1) | WO2022230487A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020376265B2 (en) * | 2019-10-28 | 2026-02-19 | Suntory Holdings Limited | Composition for sleep improvement comprising ergothioneine or salt thereof |
| WO2024038821A1 (ja) * | 2022-08-17 | 2024-02-22 | サントリーホールディングス株式会社 | フレイル予防又は改善用組成物、及び、加齢に伴う身体活動能力低下を抑制又は改善するための組成物 |
| WO2025157153A1 (zh) * | 2024-01-25 | 2025-07-31 | 南京纽邦生物科技有限公司 | 用于增强运动表现的方法及组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020110604A1 (en) * | 2000-08-11 | 2002-08-15 | Ashni Naturaceuticals, Inc. | Composition exhibiting synergistic antioxidant activity |
| JP5658479B2 (ja) | 2009-04-27 | 2015-01-28 | 株式会社岩出菌学研究所 | 脂肪減少等の活性を示す組成物 |
| CA2839244A1 (en) * | 2011-06-13 | 2012-12-20 | Entia Biosciences, Inc. | A nutritional approach to the control of anemia, diabetes and other diseases or conditions and prevention of associated comorbid states with the use of ergothioneine |
| US20150157648A1 (en) * | 2012-06-26 | 2015-06-11 | Entia Biosciences, Inc. | Nutritional approach to improving athletic performance and reducing injury with l-ergothioneine and/or vitamin d2 |
| JP5904378B2 (ja) * | 2013-02-28 | 2016-04-13 | 株式会社エル・エスコーポレーション | 抗うつ剤 |
| CN112352046A (zh) * | 2018-06-29 | 2021-02-09 | 长濑产业株式会社 | 麦角硫因、抗坏血酸2-葡糖苷、抗坏血酸和它们的组合的成肌分化促进作用 |
-
2022
- 2022-03-25 US US18/285,409 patent/US20240180876A1/en active Pending
- 2022-03-25 WO PCT/JP2022/014221 patent/WO2022230487A1/ja not_active Ceased
- 2022-03-25 JP JP2023517167A patent/JPWO2022230487A1/ja active Pending
- 2022-03-25 CN CN202280030901.8A patent/CN117202904A/zh active Pending
- 2022-03-25 EP EP22795405.4A patent/EP4331580A4/en active Pending
- 2022-03-25 AU AU2022267109A patent/AU2022267109A1/en active Pending
- 2022-04-21 TW TW111115162A patent/TW202308616A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4331580A1 (en) | 2024-03-06 |
| EP4331580A4 (en) | 2025-03-19 |
| US20240180876A1 (en) | 2024-06-06 |
| WO2022230487A1 (ja) | 2022-11-03 |
| CN117202904A (zh) | 2023-12-08 |
| AU2022267109A1 (en) | 2023-10-12 |
| JPWO2022230487A1 (https=) | 2022-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202308616A (zh) | 用於增加紅血球及／或血紅素之組成物 | |
| JP7757450B2 (ja) | エルゴチオネイン又はその塩を含有する睡眠改善用組成物 | |
| JP7764471B2 (ja) | 腎機能の低下抑制又は改善用組成物 | |
| JP7796116B2 (ja) | 抗不安用組成物 | |
| TW202423421A (zh) | 預防或改善衰弱用之組成物，及抑制或改善高齡所伴隨之身體活動力降低用之組成物 | |
| US20240189284A1 (en) | Composition for promoting lipolysis | |
| JP7796117B2 (ja) | 血中コレステロール値改善用組成物 | |
| HK40103316A (zh) | 红血球及/或血红蛋白增加用组合物 | |
| CN121001582A (zh) | 含有麦角硫因或其盐的用于预防、减轻或改善中暑或脱水症的组合物及用于调节细胞内外水分的组合物 | |
| WO2024172002A1 (ja) | エルゴチオネインを含有する血管拡張用組成物 | |
| HK40103317A (zh) | 肾功能的降低抑制或改善用组合物 | |
| TW202448445A (zh) | 含有麥角硫因之肌肉萎縮抑制用組成物及Ｓｒｃ酪胺酸激酶阻礙用組成物 | |
| HK40104490A (zh) | 脂肪分解促进用组合物 | |
| HK40075030A (en) | Composition for sleep improvement comprising ergothioneine or salt thereof | |
| HK40104913A (zh) | 抗焦虑用组合物 |